OP007/#276 Phase I study of mirvetuximab soravtansine (MIRV) and rucaparib for recurrent endometrial, ovarian, fallopian tube or primary peritoneal cancer

F Backes; J Fowler; L Copeland; L Wei; D O’Malley; D Cohn; C Cosgrove; J Hays; K Bixel

doi:10.1136/ijgc-2021-IGCS.24

Article info

Oral Featured Posters

OP007/#276 Phase I study of mirvetuximab soravtansine (MIRV) and rucaparib for recurrent endometrial, ovarian, fallopian tube or primary peritoneal cancer

Free

Authors

F Backes The Ohio State University, Obstetrics and Gynecology; Division of Gynecologic Oncology, Columbus, USA PubMed articles Google scholar articles
J Fowler The Ohio State University, Obstetrics and Gynecology; Division of Gynecologic Oncology, Columbus, USA PubMed articles Google scholar articles
L Copeland The Ohio State University, Obstetrics and Gynecology; Division of Gynecologic Oncology, Columbus, USA PubMed articles Google scholar articles
L Wei The Ohio State University, Center For Biostatistics, Columbus, USA PubMed articles Google scholar articles
D O’Malley The Ohio State University, Obstetrics and Gynecology; Division of Gynecologic Oncology, Columbus, USA PubMed articles Google scholar articles
D Cohn The Ohio State University, Obstetrics and Gynecology; Division of Gynecologic Oncology, Columbus, USA PubMed articles Google scholar articles
C Cosgrove The Ohio State University, Obstetrics and Gynecology; Division of Gynecologic Oncology, Columbus, USA PubMed articles Google scholar articles
J Hays The Ohio State University, Division of Medical Oncology, Columbus, USA PubMed articles Google scholar articles
K Bixel The Ohio State University, Obstetrics and Gynecology; Division of Gynecologic Oncology, Columbus, USA PubMed articles Google scholar articles

Citation

Backes F, Fowler J, Copeland L, et al

OP007/#276 Phase I study of mirvetuximab soravtansine (MIRV) and rucaparib for recurrent endometrial, ovarian, fallopian tube or primary peritoneal cancer

International Journal of Gynecologic Cancer 2021;31:A13-A14.

Publication history

First published November 1, 2021.

Online issue publication

November 01, 2021

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Main menu

Authors

Citation

Publication history

Request permissions

Copyright information

Log in using your username and password

Main menu

Log in using your username and password

You are here

Authors

Citation

Publication history

Request permissions

Copyright information

Read the full text or download the PDF:

Log in using your username and password